Multiplex PCR performed of bronchoalveolar lavage fluid increases pathogen identification rate in critically ill patients with pneumonia: a pilot study

Abstract

BackgroundIn critically ill patients with pneumonia, accurate microorganism identification allows appropriate antibiotic treatment. In patients undergoing bronchoalveolar lavage (BAL), direct examination of the fluid using Gram staining provides prompt information but pathogen identification accuracy is low. Culture of BAL fluid is actually the reference, but it is not available before 24 to 48 h. In addition, pathogen identification rate observed with direct examination and culture is decreased when antibiotic therapy has been given prior to sampling. We therefore assessed, in critically ill patients with suspected pneumonia, the performance of a multiplex PCR (MPCR) to identify pathogens in BAL fluid. This study is a prospective pilot observation.MethodsWe used a MPCR detecting 20 types of microorganisms. Direct examination, culture, and MPCR were performed on BAL fluid of critically ill patients with pneumonia suspicion. The final diagnosis of infective pneumonia was retained after the medical chart was reviewed by two experts. Pathogen identification rate of direct examination, culture, and MPCR in patients with confirmed pneumonia was compared.ResultsAmong the 65 patients with pneumonia suspicion, the diagnosis of pneumonia was finally retained in 53 cases. Twenty nine (55%) were community-acquired pneumonia and 24 (45%) were hospital acquired. Pathogen identification rate with MPCR (66%) was greater than with culture (40%) and direct examination (23%) (p =0.01 and p <0.001, respectively). When considering only the microorganisms included in the MPCR panel, the pathogen identification rate provided by MPCR reached 82% and was still higher than with culture (35%, p <0.001) and direct examination (21%, p <0.001). Pathogen identification rate provided by MPCR was not modified in the case of previous antibiotic treatment (66% vs. 64%, NS) and was still better than with culture (23%, p <0.001).ConclusionsThe results of this pilot study suggest that in critically ill patients, MPCR performed on BAL fluid could provide higher identification rate of pathogens involved in pneumonia than direct examination and culture, especially in patients having received antimicrobial treatment.

Rapid syndromic molecular testing in pneumonia: The current landscape and future potential

“…sensitivity by also detecting genotypic markers of resistance. Multiple studies have demonstrated the superior diagnostic accuracy of PCR based platforms for detecting bacterial pathogens in the sputum compared with standard culture [16][17][18][19] . This review will discuss the commercially available syndromic molecular panels for pneumonia, their potential clinical impact and the challenges to implementing them as a 'front line' diagnostic test.…”

Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections

“…Recent years' development in molecular diagnostic methods has led to a markedly increased availability of both commercial and in-house developed diagnostic panels targeting viruses and atypical bacterial pathogens [3]. However, examples of panels targeting typical respiratory bacteria are few [4][5][6], and molecular panels intended for LRTI diagnostics are even more scarce [7][8][9][10]. Methods combining targets for typical bacterial pathogens, atypical bacteria and viruses have so far been limited to qPCR-based panels, requiring a separate sample extraction step [8][9][10], which limit their use to larger clinical microbiology laboratories during working hours.…”

Broad-Range Detection of Microorganisms Directly from Bronchoalveolar Lavage Specimens by PCR/Electrospray Ionization-Mass Spectrometry

“…Diagnostic PCR-kits designed for sepsis diagnosis, e.g. LightCycler SeptiFast from Roche Diagnostics [11] have broader coverage but lack important respiratory pathogens. Similarly, poor performance and insufficient coverage has been reported for the Unyvero multiplex PCR device (Curetis AG) for direct point-of-care detection of respiratory pathogens [12, 13].…”